SAB BIO has announced a $175 million private placement financing to fund its pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly ...

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune ...

On 23 January 2025, the Securities and Exchange Commission (SEC) repealed the infamous Staff Accounting Bulletin (SAB) 121 with the publication of the already much-lauded SAB 122.[1] With President ...

SAB-142 is a human alternative to rabbit anti-thymocyte globulin (ATG). SAB-142’s mechanism of action is analogous to that of rabbit ATG, which has been clinically validated in multiple clinical ...

Issued on March 31, 2022, SAB 121 required public companies holding crypto on behalf of their customers to record customer-held crypto assets on their balance sheets as both an asset and a ...

Controversial Securities and Exchange Commission accounting guidance known as SAB 121 has been rescinded. SAB 121 has been viewed as a significant obstacle preventing banks from providing custody ...

Forbes contributors publish independent expert analyses and insights. Shaping the future of banking with bitcoin. (Full disclosure: I’m helping build Coinbits.app, a bitcoin banking platform.) In a ...

Community members argued that encouraging banks to hold other people’s Bitcoin strays from the original vision of its creator, Satoshi Nakamoto. The US Securities and Exchange Commission rescinded ...

On Tuesday, SAB BIO (NASDAQ:SABS) released topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its primary safety and pharmacodynamic ...

The Single-antigen Bead (SAB) assay has revolutionized the detection of anti-HLA antibodies, which are critical in transplantation medicine. Despite its advantages, several limitations and challenges ...